Psyence Biomedical (PBM) Competitors $5.65 +0.31 (+5.81%) Closing price 04:00 PM EasternExtended Trading$5.60 -0.06 (-0.97%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBM vs. CTXR, NKGN, PHXM, CSCI, BCDA, PHIO, EQ, AIMD, SNSE, and GLYCShould you be buying Psyence Biomedical stock or one of its competitors? The main competitors of Psyence Biomedical include Citius Pharmaceuticals (CTXR), NKGen Biotech (NKGN), PHAXIAM Therapeutics (PHXM), COSCIENS Biopharma (CSCI), BioCardia (BCDA), Phio Pharmaceuticals (PHIO), Equillium (EQ), Ainos (AIMD), Sensei Biotherapeutics (SNSE), and GlycoMimetics (GLYC). These companies are all part of the "pharmaceutical products" industry. Psyence Biomedical vs. Its Competitors Citius Pharmaceuticals NKGen Biotech PHAXIAM Therapeutics COSCIENS Biopharma BioCardia Phio Pharmaceuticals Equillium Ainos Sensei Biotherapeutics GlycoMimetics Psyence Biomedical (NASDAQ:PBM) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk. Do institutionals and insiders believe in PBM or CTXR? 77.4% of Psyence Biomedical shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 3.6% of Psyence Biomedical shares are held by insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer PBM or CTXR? In the previous week, Citius Pharmaceuticals had 2 more articles in the media than Psyence Biomedical. MarketBeat recorded 4 mentions for Citius Pharmaceuticals and 2 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 0.93 beat Citius Pharmaceuticals' score of 0.47 indicating that Psyence Biomedical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Psyence Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend PBM or CTXR? Citius Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 2,423.81%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Psyence Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Psyence Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 Is PBM or CTXR more profitable? Psyence Biomedical's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Psyence BiomedicalN/A N/A N/A Citius Pharmaceuticals N/A -58.63%-37.67% Which has more volatility and risk, PBM or CTXR? Psyence Biomedical has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Which has stronger valuation & earnings, PBM or CTXR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPsyence BiomedicalN/AN/A$1.01MN/AN/ACitius PharmaceuticalsN/AN/A-$39.14MN/AN/A SummaryCitius Pharmaceuticals beats Psyence Biomedical on 7 of the 12 factors compared between the two stocks. Get Psyence Biomedical News Delivered to You Automatically Sign up to receive the latest news and ratings for PBM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBM vs. The Competition Export to ExcelMetricPsyence BiomedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.22M$2.90B$5.49B$8.93BDividend YieldN/A2.69%5.38%4.12%P/E RatioN/A21.2626.2019.89Price / SalesN/A279.34415.50166.23Price / Cash2.9941.8936.4957.06Price / Book0.487.508.055.39Net Income$1.01M-$55.05M$3.15B$248.50M7 Day Performance14.60%2.49%1.92%2.96%1 Month Performance21.77%7.40%4.90%6.02%1 Year Performance-96.83%5.42%35.95%20.44% Psyence Biomedical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBMPsyence Biomedical1.4826 of 5 stars$5.65+5.8%N/A-97.3%$3.22MN/A0.00N/ACTXRCitius Pharmaceuticals2.6667 of 5 stars$1.29+25.2%$54.50+4,124.8%-86.0%$10.95MN/A0.0020News CoverageAnalyst ForecastGap UpHigh Trading VolumeNKGNNKGen BiotechN/A$0.24+7.9%N/A-74.9%$10.79M$80K-0.05N/AGap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049CSCICOSCIENS BiopharmaN/A$3.39+0.9%N/AN/A$10.57M$9.59M-0.5820BCDABioCardia3.6868 of 5 stars$2.18+7.9%$25.00+1,046.8%-33.1%$10.46M$60K-0.9440Positive NewsPHIOPhio Pharmaceuticals2.7097 of 5 stars$2.21+1.4%$14.00+533.5%-59.1%$10.46MN/A-0.2010EQEquillium2.4093 of 5 stars$0.36+22.6%$3.00+743.9%-53.5%$10.36M$41.10M-0.9140AIMDAinos0.9608 of 5 stars$0.50+0.3%N/A-33.7%$10.31M$20K-0.3940High Trading VolumeSNSESensei Biotherapeutics4.8422 of 5 stars$8.47+5.1%$90.00+962.6%-25.6%$10.16MN/A-0.3740Positive NewsGLYCGlycoMimetics1.6423 of 5 stars$0.16-6.6%N/A-99.5%$10.00M$10K-0.3450Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Citius Pharmaceuticals Alternatives NKGen Biotech Alternatives PHAXIAM Therapeutics Alternatives COSCIENS Biopharma Alternatives BioCardia Alternatives Phio Pharmaceuticals Alternatives Equillium Alternatives Ainos Alternatives Sensei Biotherapeutics Alternatives GlycoMimetics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBM) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBM Stock Alerts